MSD’s Januvia Logs 1st Sales Decline in Japan on Re-Pricing

MSD K.K. President Tony Alvarez MSD K.K.’s flagship diabetes drug Januvia (sitagliptin) saw its NHI price-based sales slip 5% year on year in January-June, marking the first drop since the product hit the Japan market in 2009. Coupled with bruising...read more